Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 6Phase 3 5Phase 1/2 3Phase NA 2Phase EARLY_PHASE1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1

Conditions

Lymphoma, Large B-Cell, Diffuse 22Breast Neoplasms 19Lymphoma 14Sarcoma 13Lymphoma, Non-Hodgkin 9Lymphoma, Follicular 8Lymphoma, B-Cell 8Hodgkin Disease 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Immunoblastic Lymphadenopathy 5Ovarian Neoplasms 4Neoplasms 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Large-Cell, Anaplastic 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Hepatocellular 4Recurrence 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Primary Effusion 3Chondrosarcoma 3Triple Negative Breast Neoplasms 2Solitary Fibrous Tumors 2Sarcoma, Clear Cell 2Plasmablastic Lymphoma 2Osteosarcoma 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Liver Neoplasms 2

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Doxorubicin × Clear all
NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Oncotherapeutics

Phase 1/2 Completed
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT00439296 2021-03-17

ABT-751 With Chemotherapy for Relapsed Pediatric ALL

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1/2 Terminated
9 enrolled 12 charts
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00440726 2020-02-19

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1/2 Completed
31 enrolled 15 charts
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡